Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083815860> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2083815860 endingPage "430" @default.
- W2083815860 startingPage "425" @default.
- W2083815860 abstract "Trastuzumab is an established component of breast cancer combination regimens, but data on the safety and efficacy of single-agent therapy is sparse.70 Patients with HER2-overexpressing breast cancer after failure of at least one chemotherapy regimen for metastatic disease were recruited from 28 institutions. HER2 overexpression was 3+ in 96% and 2+/FISH+ in 4%. Treatment consisted of a loading dose of 4 mg/kg trastuzumab in the first week and 2 mg/kg per week thereafter, continued until progression.Trastuzumab treatment duration ranged from 1 to 66 weeks (median: 12). Objective responses (complete response (CR)/partial response (PR)) were seen in 12/62 fully evaluable patients (19%; 2 CR) while another 29% showed stabilization of the disease. Half of the patients had experienced progression after 13 weeks while median duration of response reached 44 weeks. Median survival was 68 weeks with nearly one-third of the patients still alive after more than 3 years. The most frequent adverse reaction was infusion-related syndrome arising during the first administration. Significant cardiovascular problems were detected in 3 cases, all with anthracycline pretreatment.Patients with metastatic breast cancer overexpressing HER2 may benefit from trastuzumab single-drug treatment, predominantly due to its favourable safety profile." @default.
- W2083815860 created "2016-06-24" @default.
- W2083815860 creator A5011410319 @default.
- W2083815860 creator A5012681752 @default.
- W2083815860 creator A5013148496 @default.
- W2083815860 creator A5047695952 @default.
- W2083815860 creator A5049792647 @default.
- W2083815860 creator A5071658752 @default.
- W2083815860 creator A5081805077 @default.
- W2083815860 creator A5082636888 @default.
- W2083815860 date "2010-01-01" @default.
- W2083815860 modified "2023-09-25" @default.
- W2083815860 title "Trastuzumab Single-Drug Therapy after Failure of Cytotoxic Treatment for Metastatic Breast Cancer" @default.
- W2083815860 doi "https://doi.org/10.1159/000318144" @default.
- W2083815860 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20838057" @default.
- W2083815860 hasPublicationYear "2010" @default.
- W2083815860 type Work @default.
- W2083815860 sameAs 2083815860 @default.
- W2083815860 citedByCount "6" @default.
- W2083815860 countsByYear W20838158602014 @default.
- W2083815860 countsByYear W20838158602018 @default.
- W2083815860 countsByYear W20838158602022 @default.
- W2083815860 countsByYear W20838158602023 @default.
- W2083815860 crossrefType "journal-article" @default.
- W2083815860 hasAuthorship W2083815860A5011410319 @default.
- W2083815860 hasAuthorship W2083815860A5012681752 @default.
- W2083815860 hasAuthorship W2083815860A5013148496 @default.
- W2083815860 hasAuthorship W2083815860A5047695952 @default.
- W2083815860 hasAuthorship W2083815860A5049792647 @default.
- W2083815860 hasAuthorship W2083815860A5071658752 @default.
- W2083815860 hasAuthorship W2083815860A5081805077 @default.
- W2083815860 hasAuthorship W2083815860A5082636888 @default.
- W2083815860 hasConcept C121608353 @default.
- W2083815860 hasConcept C126322002 @default.
- W2083815860 hasConcept C141071460 @default.
- W2083815860 hasConcept C143998085 @default.
- W2083815860 hasConcept C197934379 @default.
- W2083815860 hasConcept C2775930923 @default.
- W2083815860 hasConcept C2776694085 @default.
- W2083815860 hasConcept C2776802502 @default.
- W2083815860 hasConcept C2778822529 @default.
- W2083815860 hasConcept C2779786085 @default.
- W2083815860 hasConcept C2781413609 @default.
- W2083815860 hasConcept C530470458 @default.
- W2083815860 hasConcept C71924100 @default.
- W2083815860 hasConcept C90924648 @default.
- W2083815860 hasConceptScore W2083815860C121608353 @default.
- W2083815860 hasConceptScore W2083815860C126322002 @default.
- W2083815860 hasConceptScore W2083815860C141071460 @default.
- W2083815860 hasConceptScore W2083815860C143998085 @default.
- W2083815860 hasConceptScore W2083815860C197934379 @default.
- W2083815860 hasConceptScore W2083815860C2775930923 @default.
- W2083815860 hasConceptScore W2083815860C2776694085 @default.
- W2083815860 hasConceptScore W2083815860C2776802502 @default.
- W2083815860 hasConceptScore W2083815860C2778822529 @default.
- W2083815860 hasConceptScore W2083815860C2779786085 @default.
- W2083815860 hasConceptScore W2083815860C2781413609 @default.
- W2083815860 hasConceptScore W2083815860C530470458 @default.
- W2083815860 hasConceptScore W2083815860C71924100 @default.
- W2083815860 hasConceptScore W2083815860C90924648 @default.
- W2083815860 hasIssue "8-9" @default.
- W2083815860 hasLocation W20838158601 @default.
- W2083815860 hasLocation W20838158602 @default.
- W2083815860 hasOpenAccess W2083815860 @default.
- W2083815860 hasPrimaryLocation W20838158601 @default.
- W2083815860 hasRelatedWork W1971716849 @default.
- W2083815860 hasRelatedWork W1976609613 @default.
- W2083815860 hasRelatedWork W2013223170 @default.
- W2083815860 hasRelatedWork W2030434439 @default.
- W2083815860 hasRelatedWork W2040689610 @default.
- W2083815860 hasRelatedWork W2082219531 @default.
- W2083815860 hasRelatedWork W2218005127 @default.
- W2083815860 hasRelatedWork W2388730008 @default.
- W2083815860 hasRelatedWork W2401765432 @default.
- W2083815860 hasRelatedWork W2591616149 @default.
- W2083815860 hasVolume "33" @default.
- W2083815860 isParatext "false" @default.
- W2083815860 isRetracted "false" @default.
- W2083815860 magId "2083815860" @default.
- W2083815860 workType "article" @default.